Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

City of Hope scientist receives $9.28M for CAR T trial for metastatic breast cancer

August 15, 2019 | Letisia Marquez

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases

October 30, 2018 | City of Hope

City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.

Groundbreaking new CAR T cell trial opens for patients with breast cancer that has spread to the brain

October 30, 2018 | Letisia Marquez

A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants. 

Parker Institute for Cancer Immunotherapy Welcomes Stephen J. Forman, M.D.

September 27, 2018 | Letisia Marquez

City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.

CAR T researcher Saul Priceman wants to teach your body to fight cancer

September 13, 2018 | Letisia Marquez

Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.

City of Hope's Stephen J. Forman Joins Parker Institute for Cancer Immunotherapy

July 16, 2018 | Letisia Marquez

City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.

CAR T Laboratory Research Yields Promising Prostate Cancer Results

April 17, 2018 | Letisia Marquez

City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.